Applied Biosystems shares rose $2. The merged company will generate $3. Shares of Applied Biosystems were up $2. The 17 percent premium on the deal is far lower than other recent acquisitions in the biotechnology industry.
The purchase price of $38 per share in cash and stock represents a premium of 17 percent over Applied Biosystems’ closing price on Wednesday and a premium of 12 percent over its average closing price in the past 30 days. 8 percent, to $34. ’s scientific-instrument company Applied Biosystems in a $6. Profit from Insider Trading Data with Our NEW InsiderInsights.
Up 40. In a statement, the companies valued the transaction at $6. The companies expect the merger to close in the fall. Under the deal announced Thursday morning, Applera-Applied Biosystems shareholders will receive $38 for each share in a combination of 55% in Invitrogen common stock and 45% cash.
The total debt of the combined company will be $3. The $38 per-share value represents a premium of 17% to Applied Biosystems’s closing price Wednesday. Invitrogen shares fell 6 percent on news of the deal, while Applied Biosystems rose more than 8 percent. Applera Chief Executive Tony White said the company’s board previously engaged Morgan Stanley to examine its options, including the sale of Applied Biosystems.
32, or 7. 5 billion. -based Invitrogen Corp. “Invitrogen and Applied Biosystems will be well positioned to compete in several rapidly growing markets, such as next generation sequencing, cell biology, applied markets and emerging geographies,” the companies said in a statement.
“It makes sense in terms of their expertise in molecular biology, efficiencies in combined sales forces, overlap on product line and intellectual property interests,” said Deutsche Bank analyst Ross Muken. Introductory $50 savings — limited time. 4% over 3 years! If you’re looking for gains like this, check out InsiderInsights, where Jonathan Moreland gives you both long and short picks — complete with buy, sell, hold ratings — that are based on his exhaustive research and analysis. -based Applied Biosystems is expected to close in the fall.
7 billion cash and stock deal. 85, or 11. The purchase price will be paid 45 percent in cash and the rest in stock. 4 billion.
On closing, Invitrogen shareholders would own a majority of the merged company, which will be named Applied Biosystems Inc and boast 3,000 sales representatives worldwide. The deal has a break-up fee of $150 million. 99 in morning trading Thursday, while Invitrogen shares fell $4. 50.
Recent deals have had an average premium of 63 percent, according to a report from Credit Suisse analysts. 7 billion to form a top provider of research tools for the life sciences industry, the companies said on Thursday. The combined company will be called Applied Biosystems and will be headquartered in Carlsbad. Such a combination was a source of speculation at a conference in Denver last week, he added.
